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S18 Journal of Thoracic Oncology Vol. 11 No. 2Sphosphorylation of downstream targets Akt and ERK
MAP kinase at a concentration of approximately 100nM
and blocked the kinase activity of an EGFR mutant,
T790M, which confers resistance to front-line EGFR in-
hibitors such as Tarceva. Compound LL001 induced full
remission of subcutaneous tumors using the human
NSCLC cell line H1975 (T790M/L858Rþ). Most notably,
pharmacokinetic studies showed that LL001, when
administered at a concentration of 150mg/kg in mice,
showed no signs of toxicity and accumulated in the brain
at concentrations ranging from 12-171 times higher than
the GI50 for inhibition of EGFRþ NSCLC cell line prolif-
eration in vitro.
In order to determine whether LL001 could effec-
tively treat NSCLC brain metastases, we developed an
intracranial injection orthotopic xenograft model for
the study of NSCLC brain lesions. We found that LL001
could induce complete remission of brain tumors in
67% of mice injected with the human NSCLC cell line
HCC827-luciferase, which expresses an exon 19 dele-
tion mutant of EGFR. Compound LL001 (75mg/kg/day)
reduced tumor burden in the brain to undetectable
levels by in vitro imaging (IVIS) and performed signif-
icantly better than Tarceva, a reference compound. We
conclude that compound LL001 crosses the blood brain
barrier at levels sufﬁcient to block the growth of
EGFRþ NSCLC brain metastases and therefore may be
therapeutically useful for a critically underserved pa-
tient population.Gold nanorod immunoassay to quantify
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selected for anti-EGFR therapyChuck Caldwell, Raghuraman Kannan,
Gerald Arthur, Dmitry Shin, Ilker Ersoy,
Richard Hammer University of Missouri-Columbia,
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Non-small cell lung cancer (NSCLC) is a subtype of lung
cancer that is the leading cause of cancer-related mor-
tality. The average 5-year relative survival rate for
NSCLC patients is estimated to be 15.7% depending on
the stage of diagnosis. 224,210 new cases of lung can-
cer, and 159,260 deaths were reported in the year
2014. Out of these reported numbers, NSCLC makes up
almost 80% of cases. More importantly the patients are
often found in late stages due to ineffective diagnosis
and relative insensitivity to chemotherapy. NSCLC is a
complex disease due to presence of large number of
genomic alterations, such as EGFR overexpression that
has been reported to be overexpressed anywhere from
43-89% depending on factors such as stage, ethnicity,and diagnostic method used. EGFR-expressing lung
cancers are treated with anti-EGFR drugs such as
monoclonal antibodies or small molecule tyrosine ki-
nase inhibitors. Upon treatment with tyrosine kinase
inhibitors (TKIs), NSCLC tumors have shown to acquire
resistance to TKIs through mutations that circumvent
the EGFR pathways targeted. One marker that has been
shown to arise in tumors treated with anti-EGFR ther-
apies is the c-Met (HGF) receptor. Once a patient has
undergone several months of EGFR targeted therapy,
often times a subsequent biopsy will show that the
tumor now expresses a large amount of c-Met protein
instead of the previously diagnosed EGFR expression.
We will thus explore the notion that for a substantial
amount of EGFR-expressing NSCLC tissues, there will be
a population of cells which overexpress the c-Met re-
ceptor at the stage of initial diagnosis which are
allowed to continue growth since EGFR is the only
therapeutic target utilized for the patient treatment. As
a result, a better recommendation for patient treatment
would include therapies targeted both at c-Met and
EGFR. For this study, we have acquired NSCLC tissues
from patients who have been treated with anti-EGFR
therapy. To assess levels of EGFR and c-Met in the tis-
sues, we use our platform IHC nanotechnology con-
sisting of gold nanorods (GNR) targeted to either
receptor by means of surface modiﬁcation. By adding a
modiﬁed peptide speciﬁc for EGFR or c-Met to the
surface of the gold nanorod, we assess levels of both
EGFR and c-Met in the tissues through imaging. GNR
stained tissue images can be analyzed quantitatively
through speciﬁc image processing algorithms, allowing
for a precise, accurate method of diagnosis compared to
conventional IHC. Tissue levels of c-Met present and the
patient response to anti-EGFR treatment will then be
compared to determine if the patient would likely
beneﬁt from initial treatment targeted at both c-Met
and EGFR.
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Lung cancer remains the leading cause of cancer
mortality in United States and globally. Pemetrexed
February 2016 Abstracts S19combined with platinum chemotherapy is speciﬁcally
indicated for treatment of non-squamous non-small cell
lung cancer (non-sq NSCLC). Pemetrexed is a folate-
analog metabolic inhibitor that disrupts folate-depen-
dent processes essential for cell replication. Pemetrexed
inhibits thymidylate synthase (TS), dihydrofolate
reductase (DHFR), and glycinamide ribonucleotide for-
myltransferase (GARFT), which are folate-dependent
enzymes involved in the de novo biosynthesis of
thymidine and purine nucleotides. Folate receptor alpha
(FRalpha) is a folate/antifolate transporter protein that
is overexpressed by a number of epithelial tumors. The
purpose of this study is to identify proteomic biomarkers
predictive of response to pemetrexed-based chemo-
therapy in non-sq NSCLC.
Methods: Patients with advanced non-sq NSCLC who
received pemetrexed-based chemotherapy at West
Virginia University from 2009 to 2014 were retro-
spectively identiﬁed. Formalin-ﬁxed, parafﬁn-
embedded tumor biopsies were laser microdissected,
solubilized, enzymatically digested and subjected to
quantitative proteomic analysis. A multiplexed,
selected reaction monitoring (SRM) mass spectrom-
etry (MS) assay was used to determine the absolute
levels of 46 different candidate proteomic markers,
including those in the folate receptor pathway. TS
analysis was also performed by IHC. The Kaplan-Meier
method and log-rank test were used in statistical
analysis of overall survival (OS) and progression-free
survival (PFS).
Results: The 74 patients included in the study had a
median follow-up of 26 months, a median OS of 16.6
months (95%CI: 11.6 - 43.4), and a median PFS of
9.61 months (95%CI: 8.43, 12.98). There were 65
patients who received pemetrexed-based regimen as a
ﬁrst line therapy and 9 patients as subsequent salvage
treatment. In a comparison between patients who
survived >24 months and < 8 months, there were no
signiﬁcant differences between the two groups in
terms of sex, age, ECOG performance status, TNM
stage at diagnosis, and smoking history. Among the 37
patients with sufﬁcient tumor specimens available for
multiplexed proteomic analysis, 30 biomarkers were
detected with varying levels of expression. Sixteen
additional biomarkers were undetectable. TS protein
expression was detected in by SRM in 2 patients and
by IHC in 32 patients (tumor staining>1); however,
TS IHC was not predictive of outcome (PFS-HR
ratio ¼ 1.06). Patients whose tumors expressed low
levels of GARFT protein (900 amol/mg; n¼7) had
statistically signiﬁcantly longer median PFS than
those whose tumors expressed high levels of
GARFT (>900 amol/mg; n¼30) (40.6 vs. 11.4 months;p ¼ 0.014). Patients with high FRalpha protein
expression (>1510 amol/mg, n¼9) had signiﬁcantly
longer median PFS than those with low FRalpha
expression (1510 amol/mg; n¼28) (>50 vs. 11.4
months; p¼ 0.021). Moreover, the 23 patients with
both high GARFT expression (>900 amol/mg) and low
FRalpha expression (1510 amol/mg) faired consid-
erably worse than the remainder of patients (median
PFS 10.1 vs. 40.6 months; p¼0.0003).
Conclusion: Multiplexed mass spectrometry-based pro-
teomics offers a feasible and promising approach for
tumor biomarker proﬁling and quantiﬁcation to predict
therapeutic response. Of note, our results show that
FRalpha and GARFT protein expression may be predic-
tive of response to pemetrexed-based treatment in pa-
tients with non-sq NSCLC. Further investigation is
needed to validate the utility of these biomarkers for
guiding personalized treatment decisions in clinical
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Introduction and objectives: Squamous lung cancer
(SQC) is a devastating disease for which the currently
available treatments are poorly effective. There are no
licensed targeted therapeutic agents. Improving the early
detection and chemoprevention of SQC, and identifying
novel and tractable therapeutic targets are key chal-
lenges to improving outcomes.
The development of model systems that recapitulate
the human disease will facilitate the development of new
therapeutic/chemopreventive agents and new insights
into the pathobiology of SQC.
SOX2 ampliﬁcation is a frequent genetic alteration in
squamous lung cancer. We have shown that ampliﬁca-
tion and overexpression of SOX2 is an early and
consistent event in the pathogenesis of this disease.
Our hypothesis is that deregulated expression of SOX2
is a key event in the initiation of bronchial dysplasia/
squamous carcinogenesis.
Our aims are:
1) To develop a novel 3D in vitro model of human
bronchial dysplasia that recapitulates the molecu-
lar and phenotypic characteristics of the in vivo
disease
